Vantin Related Published Studies
Well-designed clinical trials related to Vantin (Cefpodoxime Proxetil)
The comparative plasma pharmacokinetics of intravenous cefpodoxime sodium and oral cefpodoxime proxetil in beagle dogs. [2007.08]
[Treatment of acute maxillary sinusitis in adults. Comparison of cefpodoxime-proxetil and amoxicillin-clavulanic acid] [2006.01]
Efficacy of cefpodoxime in the prophylaxis of recurrent pharyngotonsillitis. [2003.12]
Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women. [2003.03]
Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study. [2002.11]
Comparison of once daily cefpodoxime proxetil suspension and thrice daily cefaclor suspension in the treatment of acute otitis media in children. [1998.09]
Cefpodoxime pharmacokinetics in children: effect of food. [1998.09]
Effects of nifedipine and diltiazem on pharmacokinetics of cefpodoxime following its oral administration. [1996.12]
Cost saving of 5-day therapy with cefpodoxime proxetil versus standard 10-day beta-lactam therapy for recurrent pharyngotonsillitis in adults. A prospective general practice study. [1996.09]
Bioavailability of cefpodoxime proxetil with co-administered acetylcysteine. [1996.04]
Cefpodoxime proxetil suspension compared with cefaclor suspension for treatment of acute otitis media in paediatric patients. [1996.03]
[Comparative trial of the clinical efficacy and tolerance of cefatrizine (Cefaperos) and cefpodoxime proxetil (Orelox) in superinfections of chronic obstructive bronchopneumopathies in adults in urban practice] [1995.11]
The bioavailability of cefpodoxime proxetil tablets relative to an oral solution. [1995.05]
Multicenter trial of cefpodoxime proxetil vs. amoxicillin-clavulanate in acute lower respiratory tract infections in childhood. International Study Group. [1995.04]
Clinical experience with cefpodoxime proxetil in acute otitis media. [1995.04]
Effect of food on absorption of cefpodoxime proxetil oral suspension in adults. [1995.01]
Treatment of acute maxillary sinusitis--comparing cefpodoxime proxetil with amoxicillin. [1995]
Comparison of cefpodoxime proxetil and cefixime in the treatment of acute otitis media in infants and children. Otitis Study Group. [1994.12]
Effective short-course treatment of acute group A beta-hemolytic streptococcal tonsillopharyngitis. Ten days of penicillin V vs 5 days or 10 days of cefpodoxime therapy in children. [1994.10]
Five versus ten days treatment of streptococcal pharyngotonsillitis: a randomized controlled trial comparing cefpodoxime proxetil and phenoxymethyl penicillin. [1994]
Twice daily cefpodoxime proxetil compared with thrice daily amoxicillin/clavulanic acid for treatment of acute otitis media in children. [1994]
A comparison of cefpodoxime proxetil and cefaclor in the treatment of acute exacerbation of COPD in adults. [1993.11]
Impact of cefpodoxime proxetil and amoxicillin on the normal oral and intestinal microflora. [1993.09]
Cefpodoxime proxetil vs. penicillin V in pediatric streptococcal pharyngitis/tonsillitis. [1993.04]
Comparison of oral cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections. [1993.02]
[Clinical evaluation of cefpodoxime in respiratory tract infections] [1993.01]
Disposition of cefpodoxime proxetil in hemodialysis patients. [1992.11]
Cefpodoxime proxetil compared with amoxicillin-clavulanate for the treatment of otitis media. [1992.09]
Presence of Clostridium difficile and antibiotic and beta-lactamase activities in feces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo. [1992.09]
Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. [1992.04]
Pharmacokinetic and tolerance studies of cefpodoxime after single- and multiple-dose oral administration of cefpodoxime proxetil. [1991.12]
Comparison of oral cefpodoxime proxetil and penicillin V potassium in the treatment of group A streptococcal pharyngitis/tonsillitis. The Cefpodoxime Pharyngitis Study Group. [1991.09]
Cefpodoxime proxetil: dosage, efficacy and tolerance in adults suffering from respiratory tract infections. [1990.12]
Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia. [1990.12]
Efficacy and tolerance of cefpodoxime proxetil compared with co-amoxiclav in the treatment of exacerbations of chronic bronchitis. [1990.12]
Comparison of cefpodoxime proxetil with cefaclor in the treatment of sinusitis. [1990.12]
Five day treatment of pharyngotonsillitis with cefpodoxime proxetil. [1990.12]
Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil. [1990.06]
The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. [1989.12]
Well-designed clinical trials possibly related to Vantin (Cefpodoxime Proxetil)
Five vs. ten days of antibiotic therapy for acute otitis media in young children. [2000.05]
Prospective randomized study of antibiotic prophylaxis for nonlaparotomy surgery in benign conditions. [2000.05]
Comparative study of single-dose and three-day therapy for acute uncomplicated cystitis. [1999.02]
Treatment of acute otitis media with a shortened course of antibiotics: a meta-analysis. [1998.06.03]
Change in nasopharyngeal carriage of Streptococcus pneumoniae resulting from antibiotic therapy for acute otitis media in children. [1997.06]
Other research related to Vantin (Cefpodoxime Proxetil)
Pharmacokinetics of cefpodoxime in plasma and subcutaneous fluid following oral administration of cefpodoxime proxetil in male beagle dogs. [2011.04]
Pharmacokinetics, protein binding, and tissue distribution of orally administered cefpodoxime proxetil and cephalexin in dogs. [2010.12]
Enhancement of bioavailability of cefpodoxime proxetil using different polymeric microparticles. [2010.09]
Physicochemical and pharmacokinetic characterization of a spray-dried cefpodoxime proxetil nanosuspension. [2010.07]
Cefpodoxime Proxetil Compared with Cefixime for Treatment of Typhoid Fever in Children. [2007.11.07]
Cefpodoxime proxetil compared with cefixime for treatment of typhoid fever in children. [2007.11]
Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetil. [2007.02.01]
Investigation on physicochemical and biological differences of cefpodoxime proxetil enantiomers. [2006.10]
Disposition of orally administered cefpodoxime proxetil in foals and adult horses and minimum inhibitory concentration of the drug against common bacterial pathogens of horses. [2005.01]
Improvement of cefpodoxime proxetil oral absorption in rats by an oil-in-water submicron emulsion. [2003.09.16]
Effects of food intake and age on the pharmacokinetics of AS-924, a novel ester-type cephem antibiotic. Comparison with cefpodoxime proxetil. [2001.11]
Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients. [2001]
Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil. [2000.10]
[In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae] [1999.08]
Changes in fecal flora and comparative multiple-dose pharmacokinetics of ceftibuten, cefpodoxime proxetil and amoxycillin/clavulanate. [1999.06]
Efficacy of 5-day cefpodoxime proxetil for recurrent pharyngitis in adults. A comparative study with 10-day penicillin V or amoxycillin---clavulanate. [1997.08]
Penetration of cefpodoxime into uterine and vaginal secretions from postpartum women after a single oral dose of cefpodoxime proxetil. [1996.08]
Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections. [1996.08]
[Treatment of infectious complications affecting the skin and soft tissues with cefpodoxime proxetil] [1996.05]
Concentrations of cefpodoxime in plasma, adenoid, and tonsillar tissue after repeated administrations of cefpodoxime proxetil in children. [1996.04]
Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten. [1996.03]
Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. [1995.06]
Effect of timing of food on absorption of cefpodoxime proxetil. [1995.05]
Pharyngitis/tonsillitis: European and United States experience with cefpodoxime proxetil. [1995.04]
[Clinical evaluation of cefpodoxime proxetil, a new oral cephem, in the treatment of respiratory tract infections with the special reference to community-acquired Streptococcus Pneumoniae infections] [1995.04]
[The clinical study of cefpodoxime proxetil dry syrup preparation in the pediatric field] [1994.09]
[Evaluation of clinical efficacy and safety of cefpodoxime proxetil (CPDX-PR) in acute uncomplicated cystitis] [1994.09]
[Clinical evaluation of cefpodoxime proxetil on the treatment of bacterial infections] [1994.07]
A pharmacoeconomic comparison of amoxicillin/clavulanate and cefpodoxime proxetil in the treatment of acute otitis media. [1994.03]
Antimicrobial drug suspensions: a blinded comparison of taste of twelve common pediatric drugs including cefixime, cefpodoxime, cefprozil and loracarbef. [1994.02]
[Clinical evaluation of cefpodoxime proxetil in otorhinolaryngological infections] [1994.01]
Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis. [1993.12]
Cefpodoxime proxetil: a new, broad-spectrum, oral cephalosporin. [1993.11]
In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers. [1993.08]
In vitro antimicrobial activities of lactoferrin, its concomitant use with cefpodoxime proxetil and clinical effect of cefpodoxime proxetil. [1993.06]
Bacterial flora detected in the uterine endometrial cavity of normal puerperae on the puerperal first day and on the puerperal fifth day after incidental use of cefpodoxime proxetil. [1993.03]
Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. [1992.11]
Penetration of cefpodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients. [1992.10]
Orally administered cefpodoxime proxetil for treatment of uncomplicated gonococcal urethritis in males: a dose-response study. [1992.08]
Concentrations of cefpodoxime in serum and bronchial mucosal biopsies. [1992.07]
Cefpodoxime proxetil concentrations in head and neck tissues. [1991.01]
[RU 51807 (cefpodoxime proxetil). In vitro and in vivo antibacterial activity of a new orally administered active cephalosporin] [1991.01]
Clinical trials of cefpodoxime proxetil suspension in paediatrics. [1991]
Cefpodoxime proxetil in the treatment of skin and soft tissue infections. [1991]
Review of clinical experience in the United States with cefpodoxime proxetil in adults with uncomplicated urinary tract infections. [1991]
Cefpodoxime proxetil in the treatment of lower respiratory tract infections. [1991]
Cefpodoxime proxetil in upper respiratory tract infections. [1991]
Summary of clinical experience with cefpodoxime proxetil in adults in Japan. [1991]
Concentrations of cefpodoxime in plasma and pleural fluid after a single oral dose of cefpodoxime proxetil. [1990.12]
Concentrations of cefpodoxime in plasma and lung tissue after a single oral dose of cefpodoxime proxetil. [1990.12]
Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses. [1990.12]
Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis. [1990.05]
[Laboratory and clinical studies of cefpodoxime proxetil in pediatric field] [1989.07]
[Pharmacokinetic, bacteriological and clinical evaluation of cefpodoxime proxetil in pediatrics] [1989.07]
[Pharmacokinetic, bacteriological and clinical studies on cefpodoxime proxetil in the field of pediatrics] [1989.07]
[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field] [1989.07]
[Evaluation of cefpodoxime proxetil in the pediatric field] [1989.07]
|
